Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Serum amyloid A (SAA) is an acute-phase protein widely used as a biomarker for inflammation, infection, and disease monitoring. Accurate laboratory measurement of SAA is essential for clinical ...

Screening automation bottlenecks in high-throughput screening arise from poor instrument integration, assay variability, data ...

Overall Survival With Second-Line Pembrolizumab in Patients With Non–Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data The ability of ...

Interindividual Response Variability, Laboratory Variability or Aspirin 'Resistance'? Individual drug response is a multifactorial, highly variable trait, being the final phenotypic result of ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

One of the primary objectives for the application of flow cytometry in any testing environment should be measurement assurance, i.e., the generation of reliable and reproducible results. This goal can ...

One of the earliest examples of a vaccine biomarker assay still in use is the polio antibody neutralization assay, which evaluates the immunogenicity of different polio vaccines. This assay is used to ...